• AVITA Medical is a leading therapeutic acute wound care company
• RECELL is the flagship device in a comprehensive portfolio of wound care solutions
• Cohealyx, a new dermal matrix, has shown promising results in first patient case

AVITA Medical's Q4 and FY 2024 earnings presentation provided an overview of the company's position as a leading therapeutic acute wound care company. The presentation highlighted AVITA's mission to deliver transformative solutions that optimize wound healing and accelerate patient recovery. At the core of the company's comprehensive portfolio is the RECELL device, which facilitates epidermal replacement and wound healing. The presentation also introduced Cohealyx, a new dermal matrix that recently received FDA clearance. The first patient case with Cohealyx demonstrated promising results, with the ability to facilitate quicker wound closure and potentially reduce hospital stay duration and improve health outcomes. The presentation outlined the revenue potential of AVITA's portfolio, with the combined use of RECELL, Cohealyx, and PermeaDerm dressings offering significant revenue opportunities in the burn market alone, expanding the company's total addressable market from $450 million to $1.5 billion. The presentation also provided an overview of the company's strong commercial revenue growth trajectory, with a projected 61% year-over-year growth in FY 2025.

AVITA Medical provided the following high-importance, price-sensitive forward-looking financial guidance for FY 2025: Commercial revenue of $103 million, representing a 61% year-over-year growth.

AVITA Medical is well-positioned to continue its strong commercial growth trajectory, driven by the expanding adoption of its comprehensive portfolio of therapeutic acute wound care solutions, including the newly launched Cohealyx dermal matrix. The company is focused on delivering transformative solutions that optimize wound healing and accelerate patient recovery.